Retatrutide

Retatrutide (Eli Lilly code LY3437943) is a synthetic peptide developed by Eli Lilly designed as a triple hormone receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously. Its molecular formula is C221H342N46O68, with a molecular weight of 4731.33 g/mol, and it is catalogued under CAS number 2381089-83-2 and PubChem CID 171390338. This triple-agonist approach represents a novel advancement in peptide therapeutics beyond the dual agonists and single agonists currently characterized in metabolic research.

Structurally and conceptually, retatrutide’s design integrates three distinct receptor targets into a single peptide molecule, differentiating it from dual agonists such as tirzepatide, which only activates GIP and GLP-1 receptors, and from single agonists like semaglutide, which selectively targets the GLP-1 receptor. The inclusion of glucagon receptor agonism in retatrutide’s mechanism is intended to leverage the combined metabolic effects of all three incretin and glucagon pathways, potentially enhancing efficacy in metabolic regulation. This triple receptor engagement aims to influence energy balance, glucose homeostasis, and weight modulation through multiple complementary hormonal pathways.

Retatrutide’s development by Eli Lilly reflects a strategic evolution in peptide-based metabolic agents, building upon the clinical success of GLP-1 receptor agonists and dual incretin receptor agonists. By incorporating glucagon receptor activity, retatrutide seeks to expand the therapeutic potential of peptide agonists beyond what is achievable with dual or single receptor targeting. This molecular innovation is embodied in its peptide sequence and chemical modifications that confer receptor affinity and pharmacokinetic properties suitable for sustained receptor activation.

Currently, retatrutide remains an investigational compound with no regulatory approval or confirmed expedited designations by the U.S. Food and Drug Administration. It is available exclusively for laboratory research use through research-peptide and grey-market sources, consistent with the regulatory status of novel peptide therapeutics in early clinical development stages. Its unique triple agonist profile makes it a subject of significant interest in metabolic research, particularly for obesity and related metabolic disorders, although its use is strictly limited to preclinical and clinical research contexts.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Retatrutide (Eli Lilly, code LY3437943) is a novel triple hormone receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously. This mechanism represents an advancement beyond dual agonists such as tirzepatide, which activates GIP and GLP-1 receptors, and single agonists like semaglutide that target only GLP-1 receptors. The molecular formula of Retatrutide is C221H342N46O68, with a molecular weight of 4731.33 g/mol, registered under CAS number 2381089-83-2 and PubChem CID 171390338. Its multi-receptor activity is designed to leverage synergistic effects on metabolic pathways relevant to body weight regulation, positioning it as a significant candidate in obesity research.

The clinical research corpus for Retatrutide includes a published, peer-reviewed Phase 2 trial reported by Jastreboff AM et al. in the New England Journal of Medicine in 2023 (PMID 37366315, DOI 10.1056/NEJMoa2301972). This study evaluated multiple doses, with the 12 mg dose demonstrating a mean body weight reduction of up to 24.2% at 48 weeks. This magnitude of weight loss was the highest reported for any pharmaceutical agent in a controlled trial at the time of publication, establishing a strong evidentiary foundation for Retatrutide’s potential metabolic effects. The peer-reviewed status of this trial provides a high level of confidence in the data, as it underwent rigorous scientific scrutiny and is accessible through NIH and PubMed databases for independent verification and meta-analyses.

More recently, Eli Lilly announced topline results from the pivotal Phase 3 trial TRIUMPH-1 (NCT05929066) on May 21, 2026. This trial randomized 2,339 participants to receive Retatrutide at doses of 4 mg, 9 mg, or 12 mg, or placebo, over an extended period of 80 weeks. According to company-reported data, the 12 mg dose achieved a mean body weight change of -28.3% at 80 weeks based on the efficacy estimand. Notably, 45.3% of participants on the 12 mg dose lost 30% or more of their body weight, a proportion described in trade publications as the highest recorded for any anti-obesity medication to date. The placebo arm exhibited a mean weight change of approximately -2.2%. All three active doses met their primary and key secondary endpoints, indicating robust efficacy signals across the dose range.

It is critical to emphasize that the Phase 3 TRIUMPH-1 results remain unpublished and have not undergone peer review or independent replication. As such, while these topline data are promising and suggest enhanced efficacy relative to Phase 2 findings, researchers should interpret them cautiously until full datasets and analyses become publicly available. The distinction between peer-reviewed published data and company-announced topline results is essential for assessing the reliability and reproducibility of findings in the research context.

Regulatory oversight for Retatrutide remains investigational. The compound is not FDA approved, and no public confirmation exists regarding Fast Track or Breakthrough Therapy designations. The New Drug Application (NDA) submission is estimated for late 2026 or early 2027, with potential approval decisions expected no earlier than 2027. Until regulatory authorization is granted, Retatrutide is accessible solely through research-peptide or grey-market channels for laboratory research use, consistent with the regulatory posture of other investigational peptides.

In summary, Retatrutide represents a significant advancement in multi-receptor peptide agonists with compelling Phase 2 peer-reviewed efficacy data and encouraging Phase 3 topline results pending further validation. Its unique triple agonist profile and substantial weight reduction effects position it as a notable subject for ongoing research in metabolic regulation and obesity pharmacotherapy development.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Retatrutide (LY3437943) represents a mechanistic advancement beyond previously developed incretin-based therapies by simultaneously targeting three distinct receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple agonism differentiates it from dual agonists such as tirzepatide, which engages only GIP and GLP-1 receptors, and single agonists like semaglutide that selectively activate GLP-1 receptors. The inclusion of glucagon receptor activation adds a unique metabolic dimension, potentially enhancing energy expenditure and lipid metabolism in ways not achievable by dual or single receptor agonists alone. This integrated receptor targeting strategy underpins retatrutide’s pronounced efficacy in weight reduction observed in clinical trials.

The development code LY3437943 is an internal Eli Lilly designation reflecting this compound’s novel molecular architecture and pharmacological profile. Its molecular formula, C221H342N46O68, and substantial molecular weight of 4731.33 g/mol underscore the complexity of this peptide-based molecule designed for multi-receptor engagement. The compound’s CAS number 2381089-83-2 and PubChem CID 171390338 facilitate precise identification in chemical databases, supporting reproducibility and research traceability.

Notably, the phase 3 TRIUMPH-1 trial topline results revealed that 45.3% of participants receiving the highest 12 mg dose achieved at least 30% body weight reduction after 80 weeks. This proportion is unprecedented in the pharmacotherapy landscape for obesity, surpassing outcomes reported for other anti-obesity medications and highlighting retatrutide’s potent efficacy. The mean weight loss of 28.3% at 80 weeks further establishes its potential as a leading investigational agent. These results exceed the 24.2% mean weight loss at 48 weeks reported in the phase 2 study published in the New England Journal of Medicine, illustrating continued efficacy gains with prolonged treatment duration.

Retatrutide’s research trajectory parallels but also advances beyond the developmental paths of semaglutide and tirzepatide. While semaglutide and tirzepatide established the clinical viability of GLP-1 and dual GIP/GLP-1 receptor agonism respectively, retatrutide’s triple receptor agonism represents a strategic evolution aiming to maximize metabolic benefits through a broader receptor engagement. This progression underscores the expanding complexity and sophistication in peptide therapeutics targeting metabolic disorders.

At present, retatrutide remains investigational and is not FDA approved. It is accessible exclusively through research peptide channels for laboratory research use only, consistent with the regulatory status of other compounds in this category.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Retatrutide, a complex triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, demands rigorous quality control in its research-grade form due to its large molecular structure (C221H342N46O68, molecular weight 4731.33 g/mol). At Verified Peptides, we prioritize stringent purity and sourcing standards to ensure that our Retatrutide batches meet the high expectations required for laboratory research applications. Each lot undergoes comprehensive analytical verification, beginning with high-performance liquid chromatography (HPLC) to assess purity levels. Our HPLC protocols are designed to detect and quantify impurities, guaranteeing that Retatrutide supplied maintains a purity threshold suitable for experimental reproducibility and integrity.

In addition to purity assessment, we employ mass spectrometry to confirm the molecular identity of Retatrutide, verifying the peptide’s precise mass and structural integrity. This dual approach—HPLC purity testing combined with mass spectrometric identity confirmation—provides a robust assurance framework that the compound corresponds exactly to the expected Retatrutide sequence and molecular formula. Furthermore, each batch is accompanied by a third-party certificate of analysis (COA), which independently validates purity and identity metrics, reinforcing transparency and traceability for researchers.

Given Retatrutide’s investigational status and absence of regulatory approval, it is currently available exclusively for laboratory research use through specialized research peptide channels. Verified Peptides sources Retatrutide from manufacturers who comply with stringent synthesis and quality control practices, ensuring consistency across batches. This commitment supports researchers in obtaining reliable material for preclinical studies and pharmacological investigations, without any medical or clinical claims.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Retatrutide, as a complex triple hormone receptor agonist peptide, requires careful storage and handling to preserve its structural integrity and biological activity for research purposes. Typically supplied in lyophilized powder form, it should be stored at low temperatures, preferably at -20°C or colder, to minimize degradation. Avoid repeated freeze-thaw cycles, as these can cause peptide aggregation or loss of potency; aliquoting the lyophilized powder into single-use portions prior to freezing is recommended to prevent this. Upon reconstitution, use sterile, nuclease-free water or appropriate buffer systems as specified in your experimental protocol. Reconstituted solutions should be stored at 2–8°C and used promptly, generally within 24 to 72 hours, depending on stability data available for similar peptides, to reduce the risk of hydrolysis or microbial contamination. Extended storage of reconstituted Retatrutide at ambient temperature is not advisable. Protect the lyophilized and reconstituted peptide from light exposure, as ultraviolet light may induce structural changes. Shelf-life of the lyophilized peptide under proper storage conditions is typically several months to a year; however, specific stability data for Retatrutide remain unpublished. Researchers should perform stability assessments under their own laboratory conditions to confirm peptide integrity over time. Adhering to these storage and handling guidelines ensures maximal reproducibility and reliability in experimental applications involving Retatrutide.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.